Elinzanetant

Summary

Elinzanetant (CHEMBL4802157) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including opiate dependence and alcohol abuse.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 20
• Chemistry: 668.6 Da · C33H35F7N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802157
Name	Elinzanetant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16063568
Molecular formula	C33H35F7N4O3
Molecular weight	668.6
InChIKey	DWRIJNIPBUFCQS-DQEYMECFSA-N

SMILES: CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4C[C@H]5COCCN5C[C@H]4CO

IUPAC name: N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide

Also known as: BAY-3427080, Bay3427080, BAY3427080, Elinzanetant, NT-814, ELINZANETANT

Patent coverage: 33 distinct patent families (93 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 75 (81%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
opiate dependence	1	MONDO:0005530	EFO:0010702
alcohol abuse	1	MONDO:0002046	MONDO:0007079

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE1	12
PHASE3	4
PHASE1/PHASE2	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05587296	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05030584	PHASE3	COMPLETED	A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
NCT05042362	PHASE3	COMPLETED	A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
NCT05099159	PHASE3	COMPLETED	A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
NCT02692157	PHASE1/PHASE2	WITHDRAWN	NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study
NCT02865538	PHASE1/PHASE2	COMPLETED	Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
NCT03596762	PHASE2	COMPLETED	A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
NCT06112756	PHASE2	COMPLETED	A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
NCT04845841	PHASE1	COMPLETED	Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body
NCT04889287	PHASE1	COMPLETED	A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants
NCT04903821	PHASE1	COMPLETED	A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
NCT04981431	PHASE1	COMPLETED	A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults
NCT05028608	PHASE1	COMPLETED	A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.
NCT05061563	PHASE1	COMPLETED	A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
NCT05071729	PHASE1	COMPLETED	A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
NCT05351892	PHASE1	COMPLETED	A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants
NCT05381142	PHASE1	COMPLETED	A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years
NCT05471817	PHASE1	COMPLETED	A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants
NCT05481528	PHASE1	COMPLETED	A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
NCT06219902	PHASE1	COMPLETED	A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).